Abstract
Background
Accumulating evidence suggested that the use of metformin had more benefits for both prevention and treatment of tuberculosis (TB) than non-metformin use in patients with diabetes mellitus (DM); however, it remains to be fully elucidated on this topic. Thus, we conducted a systematic review and meta-analysis of published studies to determine the association between metformin use and TB in patients with diabetes.
Methods
The MEDLINE, EMBASE, Information Sciences Institute (ISI) Web of Science, and Cochrane CENTRAL databases were searched from their inception to 15 April 2019. Studies that evaluated the use of metformin and TB disease were included. The quality of each study was evaluated through the Newcastle-Ottawa Scale (NOS). For pooled data, the relative risk (RR) and 95% confidence intervals (CIs) were calculated; otherwise, a systematic review.
Results
Seventeen observational studies were included, all of which indicated a low risk of bias according to the NOS. The pooled analysis showed that metformin use was associated with a significantly lower active TB incidence and mortality among individuals with DM (RR = 0.51; 95% CI, 0.38–0.69, P ⩽ 0.001) and with TB-DM (RR = 0.34; 95% CI, 0.20–0.57, P ⩽ 0.001), respectively.
Conclusions
This meta-analysis indicated metformin use is related to benefits in both prevention and treatment outcomes of tuberculosis among patients with diabetes. Prospective clinical trials are needed to confirm these associations.
Similar content being viewed by others
References
World Health Organization (2018) Global tuberculosis report 2018
Narasimhan P, Wood J, Macintyre CR, Mathai D (2013) Risk factors for tuberculosis. Pulm Med 2013: 828939. https://doi.org/10.1155/2013/828939
Jeon CY, Murray MB (2008) Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 5(7):e152. https://doi.org/10.1371/journal.pmed.0050152
Dooley KE, Chaisson RE (2009) Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis 9(12):737–746. https://doi.org/10.1016/S1473-3099(09)70282-8
Baker MA, Harries AD, Jeon CY, Hart JE, Kapur A, Lonnroth K, Ottmani SE, Goonesekera SD, Murray MB (2011) The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med 9:81. https://doi.org/10.1186/1741-7015-9-81
Salindri AD, Kipiani M, Kempker RR, Gandhi NR, Darchia L, Tukvadze N, Blumberg HM, Magee MJ (2016) Diabetes reduces the rate of sputum culture conversion in patients with newly diagnosed multidrug-resistant tuberculosis. Open Forum Infect Dis 3(3):ofw126. https://doi.org/10.1093/ofid/ofw126
Jimenez-Corona ME, Cruz-Hervert LP, Garcia-Garcia L, Ferreyra-Reyes L, Delgado-Sanchez G, Bobadilla-Del-Valle M, Canizales-Quintero S, Ferreira-Guerrero E, Baez-Saldana R, Tellez-Vazquez N, Montero-Campos R, Mongua-Rodriguez N, Martinez-Gamboa RA, Sifuentes-Osornio J, Ponce-de-Leon A (2013) Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. Thorax 68(3):214–220. https://doi.org/10.1136/thoraxjnl-2012-201756
Harries AD, Kumar AM, Satyanarayana S, Lin Y, Zachariah R, Lonnroth K, Kapur A (2015) Diabetes mellitus and tuberculosis: programmatic management issues. Int J Tuberc Lung Dis 19(8):879–886. https://doi.org/10.5588/ijtld.15.0069
Vashisht R, Brahmachari SK (2015) Metformin as a potential combination therapy with existing front-line antibiotics for tuberculosis. J Transl Med 13:83–83. https://doi.org/10.1186/s12967-015-0443-y
Wallis RS, Hafner R (2015) Advancing host-directed therapy for tuberculosis. Nat Rev Immunol 15(4):255–263. https://doi.org/10.1038/nri3813
Singhal A, Jie L, Kumar P, Hong GS, Leow MK, Paleja B, Tsenova L, Kurepina N, Chen J, Zolezzi F, Kreiswirth B, Poidinger M, Chee C, Kaplan G, Wang YT, De Libero G (2014) Metformin as adjunct antituberculosis therapy. Sci Transl Med 6(263):263ra159. https://doi.org/10.1126/scitranslmed.3009885
Pan SW, Yen YF, Kou YR, Chuang PH, Su VYF, Feng JY, Chan YJ, Su WJ (2018) The risk of TB in patients with type 2 diabetes initiating metformin vs sulfonylurea treatment. Chest 153(6):1347–1357. https://doi.org/10.1016/j.chest.2017.11.040
Degner NR, Wang JY, Golub JE, Karakousis PC (2018) Metformin use reverses the increased mortality associated with diabetes mellitus during tuberculosis treatment. Clin Infect Dis: an Official Publication of the Infectious Diseases Society of America 66(2):198–205. https://doi.org/10.1093/cid/cix819
Ma Y, Pang Y, Shu W, Liu YH, Ge QP, Du J, Li L, Gao WW (2018) Metformin reduces the relapse rate of tuberculosis patients with diabetes mellitus: experiences from 3-year follow-up. Eur J Clin Microbiol Infect Dis: Official Publication of the European Society of Clinical Microbiology 37(7):1259–1263. https://doi.org/10.1007/s10096-018-3242-6
Kumar NP, Moideen K, Bhootra Y, Nancy A, Viswanathan V, Shruthi BS, Sivakumar S, Natarajan M, Kornfeld H, Babu S (2019) Elevated circulating levels of monocyte activation markers among tuberculosis patients with diabetes co-morbidity. Immunology 156(3):249–258. https://doi.org/10.1111/imm.13023
Yew WW, Chang KC, Chan DP, Zhang Y (2019) Metformin as a host-directed therapeutic in tuberculosis: Is there a promise? Tuberculosis (Edinb) 115:76–80. https://doi.org/10.1016/j.tube.2019.02.004
Tiberi S, du Plessis N, Walzl G, Vjecha MJ, Rao M, Ntoumi F, Mfinanga S, Kapata N, Mwaba P, McHugh TD, Ippolito G, Migliori GB, Maeurer MJ, Zumla A (2018) Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis 18(7):e183–e198. https://doi.org/10.1016/s1473-3099(18)30110-5
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62(10): e1–34. DOI https://doi.org/10.1016/j.jclinepi.2009.06.006
Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605. https://doi.org/10.1007/s10654-010-9491-z
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558. https://doi.org/10.1002/sim.1186
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188
Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719–748
Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Bmj 315(7109):629–634
Chaimani A, Mavridis D, Salanti G (2014) A hands-on practical tutorial on performing meta-analysis with Stata. Evid Based Ment Health 17(4):111–116. https://doi.org/10.1136/eb-2014-101967
Leow MK, Dalan R, Chee CB, Earnest A, Chew DE, Tan AW, Kon WY, Jong M, Barkham T, Wang YT (2014) Latent tuberculosis in patients with diabetes mellitus: prevalence, progression and public health implications. Exp Clin Endocrinol Diabetes: Official Journal, German Society of Endocrinology and German Diabetes Association 122(9):528–532. https://doi.org/10.1055/s-0034-1377044
Lin HF, Lai SW, Chang CM, Tsai PY, Chen PC, Sung FC (2016) Anti-diabetic medication reduces risk of pulmonary tuberculosis in diabetic patients: a population-based cohort study in Taiwan. Intern Med J 23(5):458–463
Marupuru S, Senapati P, Pathadka S, Miraj SS, Unnikrishnan MK, Manu MK (2017) Protective effect of metformin against tuberculosis infections in diabetic patients: an observational study of south Indian tertiary healthcare facility. Braz J Infect Dis: an Official Publication of the Brazilian Society of Infectious Diseases 21(3):312–316. https://doi.org/10.1016/j.bjid.2017.01.001
Al-Shaer MH, Elewa H, Alkabab Y, Nazer LH, Heysell SK (2018) Fixed-dose combination associated with faster time to smear conversion compared to separate tablets of anti-tuberculosis drugs in patients with poorly controlled diabetes and pulmonary tuberculosis in Qatar. BMC Infect Dis 18(1):384. https://doi.org/10.1186/s12879-018-3309-0
Kumar NP, Moideen K, Viswanathan V, Shruthi BS, Sivakumar S, Menon PA, Kornfeld H, Babu S (2018) Elevated levels of matrix metalloproteinases reflect severity and extent of disease in tuberculosis-diabetes co-morbidity and are predominantly reversed following standard anti-tuberculosis or metformin treatment. BMC Infect Dis 18(1):345. https://doi.org/10.1186/s12879-018-3246-y
Lee MC, Chiang CY, Lee CH, Ho CM, Chang CH, Wang JY, Chen SM (2018) Metformin use is associated with a low risk of tuberculosis among newly diagnosed diabetes mellitus patients with normal renal function: a nationwide cohort study with validated diagnostic criteria. PLoS One 13(10). DOI https://doi.org/10.1371/journal.pone.0205807
Lee YJ, Han SK, Park JH, Lee JK, Kim DK, Chung HS, Heo EY (2018) The effect of metformin on culture conversion in tuberculosis patients with diabetes mellitus. Korean J Intern Med 33(5):933–940. https://doi.org/10.3904/kjim.2017.249
Lin SY, Tu HP, Lu PL, Chen TC, Wang WH, Chong IW, Chen YH (2018) Metformin is associated with a lower risk of active tuberculosis in patients with type 2 diabetes. Respirology 23(11):1063–1073. https://doi.org/10.1111/resp.13338
Tseng CH (2018) Metformin decreases risk of tuberculosis infection in type 2 diabetes patients. J Clin Med 7(9). DOI https://doi.org/10.3390/jcm7090264
Magee MJ, Salindri AD, Kornfeld H, Singhal A (2019) Reduced prevalence of latent tuberculosis infection in diabetes patients using metformin and statins. Eur Respir J 53(3). https://doi.org/10.1183/13993003.01695-2018
Novita BD, Ali M, Pranoto A, Soediono EI, Mertaniasih NM (2019) Metformin induced autophagy in diabetes mellitus—tuberculosis co-infection patients: a case study. Indian J Tuberc 66(1):64–69. https://doi.org/10.1016/j.ijtb.2018.04.003
Novita BD, Pranoto A, Wuryani, Soediono EI, Mertaniasih NM (2018) A case risk study of lactic acidosis risk by metformin use in type 2 diabetes mellitus tuberculosis coinfection patients. Indian J Tuberc 65(3):252–256. https://doi.org/10.1016/j.ijtb.2017.05.008
Kumar Nathella P, Babu S (2017) Influence of diabetes mellitus on immunity to human tuberculosis. Immunology 152(1):13–24. https://doi.org/10.1111/imm.12762
Stalenhoef JE, Alisjahbana B, Nelwan EJ, van der Ven-Jongekrijg J, Ottenhoff TH, van der Meer JW, Nelwan RH, Netea MG, van Crevel R (2008) The role of interferon-gamma in the increased tuberculosis risk in type 2 diabetes mellitus. Eur J Clin Microbiol Infect Dis: Official Publication of the European Society of Clinical Microbiology 27(2):97–103. https://doi.org/10.1007/s10096-007-0395-0
Hensel RL, Kempker RR, Tapia J, Oladele A, Blumberg HM, Magee MJ (2016) Increased risk of latent tuberculous infection among persons with pre-diabetes and diabetes mellitus. Int J Tuberc Lung Dis: the Official Journal of the International Union Against Tuberculosis and Lung Disease 20(1):71–78. https://doi.org/10.5588/ijtld.15.0457
Barron MM, Shaw KM, Bullard KM, Ali MK, Magee MJ (2018) Diabetes is associated with increased prevalence of latent tuberculosis infection: findings from the National Health and Nutrition Examination Survey, 2011–2012. Diabetes Res Clin Pract 139:366–379. https://doi.org/10.1016/j.diabres.2018.03.022
Lee PH, Fu H, Lai TC, Chiang CY, Chan CC, Lin HH (2016) Glycemic control and the risk of tuberculosis: a cohort study. PLoS Med 13(8):e1002072. https://doi.org/10.1371/journal.pmed.1002072
Restrepo BI, Fisher-Hoch SP, Pino PA, Salinas A, Rahbar MH, Mora F, Cortes-Penfield N, McCormick JB (2008) Tuberculosis in poorly controlled type 2 diabetes: altered cytokine expression in peripheral white blood cells. Clin Infect Dis: an Official Publication of the Infectious Diseases Society of America 47(5):634–641. https://doi.org/10.1086/590565
Palaci M, Dietze R, Hadad DJ, Ribeiro FK, Peres RL, Vinhas SA, Maciel EL, do Valle Dettoni V, Horter L, Boom WH, Johnson JL, Eisenach KD (2007) Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. J Clin Microbiol 45(12):4064–4066. https://doi.org/10.1128/jcm.01780-07
Salpeter S, Greyber E, Pasternak G, Salpeter E (2006) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev (1): Cd002967. https://doi.org/10.1002/14651858.CD002967.pub2
Suh S (2015) Metformin-associated lactic acidosis. Endocrinol Metab (Seoul) 30(1):45–46. https://doi.org/10.3803/EnM.2015.30.1.45
Su VY, Su WJ, Yen YF, Pan SW, Chuang PH, Feng JY, Chou KT, Yang KY, Lee YC, Chen TJ (2017) Statin use is associated with a lower risk of TB. Chest 152(3):598–606. https://doi.org/10.1016/j.chest.2017.04.170
Parihar SP, Guler R, Khutlang R, Lang DM, Hurdayal R, Mhlanga MM, Suzuki H, Marais AD, Brombacher F (2014) Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. J Infect Dis 209(5):754–763. https://doi.org/10.1093/infdis/jit550
Suissa S, Azoulay L (2012) Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 35(12):2665–2673. https://doi.org/10.2337/dc12-0788
Padmapriyadarsini C, Bhavani PK, Natrajan M, Ponnuraja C, Kumar H, Gomathy SN, Guleria R, Jawahar SM, Singh M, Balganesh T, Swaminathan S (2019) Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial. BMJ Open 9(3):e024363. https://doi.org/10.1136/bmjopen-2018-024363
Funding
This work was supported by the National Natural Science Foundation of China (Grant No. 81870015)
Authors’ contributions
ZM and HJQ both searched databases, selected studies, extracted data, analyzed data. ZM wrote the manuscript. All authors read and approved the final manuscript.
Availability of data and material
All data generated or analyzed during this study are included in this published article
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare that they have no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(DOCX 29 kb)
Supplementary Table 1
(DOCX 19 kb)
Rights and permissions
About this article
Cite this article
Zhang, M., He, Jq. Impacts of metformin on tuberculosis incidence and clinical outcomes in patients with diabetes: a systematic review and meta-analysis. Eur J Clin Pharmacol 76, 149–159 (2020). https://doi.org/10.1007/s00228-019-02786-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-019-02786-y